Insilico Medicine(3696.HK)

Challenger

AI drug discovery biotech. IPO'd on HKEX Dec 2025 (3696.HK), raised $293M. 2025 rev $56.2M. $2.75B Eli Lilly deal (2026). Founded 2014, HQ Boston.

Drug Discovery & Development
3696.HK
Visit Website
Updated April 2026

Company Overview

About Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.

Business Model & Competitive Advantage

The company operates a dual business model combining internal drug pipeline development with external platform licensing and partnerships. Insilico has secured major collaboration deals valued at billions of dollars with partners including Eli Lilly, Sanofi, Fosun Pharma, Exelixis, and Menarini. Its competitive edge lies in an end-to-end AI platform covering target discovery through clinical candidate nomination, significantly compressing traditional drug development timelines and costs.

Competitive Landscape 2025–2026

Insilico listed on the Hong Kong Stock Exchange on December 30, 2025, in the largest biotech IPO on HKEX that year, raising $293M. In March 2026, the company signed a landmark $2.75B agreement with Eli Lilly including a $115M upfront payment. Total 2025 revenue reached $56.2M. With over $393M in cash post-IPO and a robust partnership portfolio valued at over $3.5B collectively, Insilico is positioned as a leading AI-native pharma company.

Revenue
$293M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Strong Challenger

Insilico Medicine is an established challenger with significant market presence and competitive offerings in Healthcare Tech.

Growth Stage

Insilico Medicine has achieved $293M in revenue, demonstrating strong product-market fit.

Frequently Asked Questions

Compare Insilico Medicine with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

Start Comparison →
For Insilico Medicine

Claim This Profile

Are you from Insilico Medicine? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Insilico Medicine Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Insilico Medicine vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →